Due to the genetic heterogeneity observed in tumors of melanoma patients who developed resistance to BRAF inhibitors, assessing mechanisms of resistance has minimal potential to inform further treatment decisions.
Dr. Atkins offers his perspective on the “race” between the top two anti-PD1 drugs (Merck’s MK-3475 and Bristol-Myers Squibb’s nivolumab), and weighs in on where thew new agent pidilizumab fits into the picture.
Dr. Antoni Ribas, UCLA’s Jonsson Comprehensive Cancer Center and a presenter at this year’s annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs— ipilimumab (Yervoy) and vemurafenib (Zelboraf)—for the treatment of metastatic melanoma.
When you inspect moles, pay special attention to their sizes, shapes, edges, and color. A handy way to remember these features is to think of the A, B, C, D, and E of skin cancer—asymmetry, border, color, diameter, and evolving.